Snap-8 (Acetyl Glutamyl Heptapeptide-1)

Trade Name: SNAP-8™ (Lipotec S.A.U.) INCI Name: Acetyl Glutamyl Heptapeptide-1 Alternative Name: Acetyl Octapeptide-3 (reflects true 8-amino acid structure) Classification: Cosmetic Peptide, Anti-Wrinkle Neuropeptide, SNARE Complex Modulator Sequence: Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ Molecular Formula: C₄₁H₇₀N₁₆O₁₆S Developer: Lipotec S.A.U. (Barcelona, Spain) - Acquired by Lubrizol (Berkshire Hathaway) in 2012 FDA Status: NOT APPROVED (Cosmetic Ingredient - No Premarket Approval Required) Primary Use: Topical anti-wrinkle cosmeceutical formulations

Executive Summary

Snap-8 (Acetyl Glutamyl Heptapeptide-1) is a synthetic octapeptide developed as an advanced derivative of Argireline (Acetyl Hexapeptide-3), designed to provide enhanced wrinkle-reduction effects through topical application. Despite the "heptapeptide" designation in its INCI name, Snap-8 is actually composed of eight amino acids, making it an octapeptide. The compound was developed in the late 2000s by Lipotec S.A.U., a Spanish cosmeceutical company specializing in bioactive peptides for skincare applications.

Mechanism of Action: Snap-8 functions as a competitive inhibitor of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) complex, a critical protein assembly required for neurotransmitter release at neuromuscular junctions. The peptide mimics a fragment of the SNAP-25 protein, one of three core SNARE complex components. By competing with endogenous SNAP-25 for binding sites, Snap-8 destabilizes SNARE complex formation, thereby reducing the release of acetylcholine—the neurotransmitter responsible for muscle contraction. This mechanism parallels botulinum neurotoxin (Botox) but operates through a non-toxic, reversible, and topically applicable pathway.

Clinical Evidence: Human clinical trials demonstrate that Snap-8 reduces wrinkle depth by 30-63% after 28 days of twice-daily topical application, with particular efficacy for dynamic expression lines (crow's feet, forehead lines, glabellar lines). A randomized, double-blind, placebo-controlled study showed 63.13% reduction in crow's feet wrinkle depth at 28 days. In vivo testing indicates Snap-8 is approximately 30% more potent than its parent compound Argireline in inhibiting neurotransmitter-mediated muscle contractions.

Topical Delivery Challenges: As a large, hydrophilic peptide (1,075 Da molecular weight), Snap-8 faces significant skin penetration barriers. The stratum corneum, the skin's outermost lipophilic layer, effectively blocks molecules >500 Da. Advanced delivery systems (liposomes, microneedle patches, penetration enhancers) are required to achieve therapeutic dermal concentrations. Despite these challenges, clinical studies using optimized formulations have consistently demonstrated measurable wrinkle reduction.

Safety Profile: Snap-8 exhibits excellent dermatological safety in clinical trials. No severe adverse events have been reported in published studies. Common side effects are limited to mild, transient skin irritation (redness, itching) in <5% of users, typically associated with sensitive skin types or high-concentration formulations. Unlike Botox injections, Snap-8 does not carry risks of ptosis (eyelid drooping), facial asymmetry, or systemic neurotoxicity.

Regulatory Status: Snap-8 is classified as a cosmetic ingredient, not a drug. The FDA does not require premarket approval for cosmetic ingredients; manufacturers are responsible for safety substantiation. Snap-8 is widely incorporated into anti-aging skincare products marketed globally. The 2022 Modernization of Cosmetics Regulation Act (MoCRA) imposes facility registration and adverse event reporting requirements but does not alter the non-drug status of cosmetic peptides like Snap-8.

Goal Relevance:

• Reduce the appearance of wrinkles and fine lines for smoother, younger-looking skin
• Minimize crow's feet and forehead lines without invasive procedures like Botox
• Achieve a more youthful complexion by targeting dynamic expression lines
• Enhance skin firmness and elasticity through advanced skincare formulations
• Improve skin texture and appearance with a non-toxic, topical anti-aging solution

Chemical Structure and Composition

Molecular Architecture

Full Sequence: Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂

Structural Features:

1. N-terminal acetylation (Acetyl group): Enhances peptide stability by blocking aminopeptidase degradation
2. Eight amino acid chain: Glutamic acid (2x), Methionine, Glutamine, Arginine (2x), Alanine, Aspartic acid
3. C-terminal amidation (-NH₂): Protects against carboxypeptidase degradation and enhances membrane permeability
4. Hydrophilic character: High density of charged residues (Glu, Arg, Asp) imparts water solubility but limits lipid membrane penetration

Molecular Formula: C₄₁H₇₀N₁₆O₁₆S Molecular Weight: 1,075.16 Da Isoelectric Point (pI): ~5.5-6.0 (net negative charge at physiological pH due to excess acidic residues)

Nomenclature Discrepancy

INCI Name: Acetyl Glutamyl Heptapeptide-1 (seven amino acids) Actual Structure: Acetyl Octapeptide-3 (eight amino acids)

This discrepancy arises from historical naming conventions where the N-terminal acetyl group was not counted in the peptide length designation. Modern nomenclature correctly identifies Snap-8 as an octapeptide.

Comparison to Argireline (Parent Compound)

The two additional C-terminal amino acids (Ala-Asp) in Snap-8 enhance binding affinity to SNARE complex proteins, increasing inhibitory potency.

Mechanism of Action

Snap-8 operates through a biomimetic mechanism that replicates key structural elements of the SNAP-25 protein, a critical component of the SNARE complex mediating neurotransmitter release.

1. SNARE Complex Biology

SNARE Complex Components:

• SNAP-25 (Synaptosomal-Associated Protein 25 kDa) - located on presynaptic membrane
• Syntaxin-1 - membrane-anchored protein on presynaptic terminal
• VAMP/Synaptobrevin - vesicle-associated membrane protein on synaptic vesicles

Function: The SNARE complex forms a four-helix bundle that brings synaptic vesicles into close apposition with the presynaptic membrane, enabling membrane fusion and neurotransmitter exocytosis. In neuromuscular junctions, this process releases acetylcholine, which binds to nicotinic receptors on muscle fibers, triggering contraction.

2. Snap-8 as SNAP-25 Mimetic

Structural Mimicry: Snap-8 is designed to mimic the N-terminal domain of SNAP-25, which contains the binding interface for syntaxin-1. The peptide sequence shares homology with residues critical for SNARE complex assembly.

Competitive Inhibition Mechanism:

1. Binding competition: Snap-8 competes with endogenous SNAP-25 for syntaxin-1 binding sites
2. Complex destabilization: When Snap-8 occupies syntaxin-1, the four-helix SNARE bundle cannot fully assemble
3. Reduced vesicle fusion: Incomplete SNARE complexes are less efficient at catalyzing membrane fusion
4. Decreased acetylcholine release: Fewer vesicles fuse with presynaptic membrane, reducing neurotransmitter output

Result: Reduced stimulation of muscle nicotinic acetylcholine receptors → decreased muscle contraction intensity → relaxation of facial expression muscles → smoothing of dynamic wrinkles

3. Comparison to Botulinum Neurotoxin (Botox)

Key Distinction: Botox destroys SNAP-25 via enzymatic cleavage, producing long-lasting paralysis. Snap-8 competes with SNAP-25, producing milder, transient muscle relaxation that requires continuous topical application.

4. Cellular Uptake and Localization

Challenge: Snap-8 must penetrate the stratum corneum, enter the dermis, and reach neuromuscular junction terminals to exert effects.

Proposed Uptake Pathways:

• Transappendageal route: Penetration through hair follicles and sweat ducts (minor contribution)
• Intercellular lipid pathway: Passive diffusion through lipid bilayers separating corneocytes (very limited due to hydrophilicity)
• Enhanced delivery: Liposomal encapsulation, microneedle pre-treatment, iontophoresis, or chemical penetration enhancers (required for efficacy)

Dermal Concentration Threshold: Estimated 5-10 μM Snap-8 concentration at neuromuscular junctions required for measurable SNARE inhibition (based on in vitro IC₅₀ data).

Pharmacokinetics and Metabolism

Topical Absorption

Skin Penetration Barrier: The stratum corneum is composed of dead, lipid-rich corneocytes forming a hydrophobic barrier. The "500 Dalton Rule" states that molecules >500 Da have minimal passive skin penetration. Snap-8 (1,075 Da) is more than twice this threshold, severely limiting dermal bioavailability.

Penetration Kinetics (Estimated from General Peptide Data):

• Transdermal flux: <1% of applied dose reaches viable epidermis with conventional cream formulations
• Time to peak dermal concentration: 2-4 hours post-application
• Stratum corneum reservoir effect: Peptide accumulates in outermost skin layers, providing sustained release

Enhancement Strategies:

1. Liposomal encapsulation: Lipid vesicles fuse with stratum corneum lipids, delivering peptide into intercellular spaces (~3-5x enhancement)
2. Microneedle patches: Create microchannels bypassing stratum corneum (~10-20x enhancement)
3. Chemical enhancers: Propylene glycol, dimethyl sulfoxide (DMSO), oleic acid disrupt lipid bilayer organization (~2-4x enhancement)
4. Iontophoresis: Electrical current drives charged peptides through skin (~5-10x enhancement)

Dermal Bioavailability (Optimized Formulations): Estimated 3-8% of applied dose reaches dermal neuromuscular junctions (based on wrinkle reduction efficacy in clinical trials).

Distribution and Metabolism

Tissue Distribution:

• Localized to application site: Minimal systemic absorption (undetectable in plasma after topical use)
• Dermal residence time: 6-12 hours (sustained release from stratum corneum reservoir)
• No accumulation: Daily application does not produce tissue buildup

Metabolic Degradation:

• Enzymatic hydrolysis: Dermal peptidases (aminopeptidases, endopeptidases, carboxypeptidases) cleave peptide bonds
• Half-life in skin: Estimated 2-4 hours (N-terminal acetylation and C-terminal amidation extend stability)
• Metabolites: Individual amino acids (Glu, Met, Gln, Arg, Ala, Asp) reabsorbed into amino acid pool
• No CYP450 involvement: Purely peptidase-mediated degradation (no hepatic metabolism)

Elimination:

• Amino acid metabolites recycled into systemic circulation and utilized for protein synthesis
• No renal or biliary excretion of intact peptide (complete dermal metabolism)

Dosing Protocols and Administration

Clinical Trial Dosing

Standard Regimen (Published Studies):

• Concentration: 5-10% Snap-8 in topical serum or cream base
• Application frequency: Twice daily (morning and evening)
• Application site: Areas with dynamic wrinkles (crow's feet, forehead, glabellar region)
• Duration: Minimum 28 days for measurable efficacy (some studies extend to 12 weeks)

Application Volume:

• Periorbital area (crow's feet): 2-3 drops serum (~0.1 mL) per eye
• Forehead lines: 3-5 drops (~0.15 mL)
• Glabellar lines (frown lines): 2-3 drops (~0.1 mL)

Commercial Product Formulations

Typical Snap-8 Concentrations:

• Low potency: 2-5% (entry-level anti-aging products)
• Medium potency: 5-10% (clinical-strength serums)
• High potency: 10-15% (professional/medical-grade formulations)

Common Co-Ingredients:

• Hyaluronic acid: Provides hydration and plumping effect (synergistic wrinkle reduction)
• Vitamin C (ascorbic acid): Antioxidant protection and collagen synthesis stimulation
• Retinol: Enhances cell turnover and collagen remodeling
• Matrixyl (palmitoyl pentapeptide-4): Collagen-stimulating peptide (complementary mechanism)
• Argireline: Often combined with Snap-8 for enhanced SNARE inhibition

Application Technique

Optimal Method:

1. Cleanse skin: Remove makeup, oil, and debris (enhances peptide penetration)
2. Apply to damp skin: Light moisture enhances hydrophilic peptide absorption
3. Gentle patting: Use fingertips to pat serum into skin (avoid rubbing, which may denature peptide)
4. Target wrinkle-prone areas: Focus application on expression lines (not uniformly across entire face)
5. Allow absorption: Wait 2-3 minutes before applying moisturizer or sunscreen
6. Consistent twice-daily use: Morning and evening application required for cumulative effect

Storage of Products:

• Store at room temperature (15-25°C) away from direct sunlight
• Refrigeration may extend peptide stability in opened products
• Discard after 6-12 months post-opening (peptide degradation over time)

Clinical Research and Evidence Base

Pivotal Clinical Trials

Study 1: Randomized, Double-Blind, Placebo-Controlled Peptide Serum Trial (2021)

• Citation: Roh E, et al. "A Randomized, Double-blind, Placebo-controlled Clinical Study Investigating the Efficacy and Tolerability of a Peptide Serum Targeting Expression Lines." J Cosmet Dermatol 2021; 20(6): 1889-1897. [PMID: 34105237]
• Design: 45 female subjects (ages 35-60) with moderate-to-severe crow's feet and forehead lines
• Intervention: Snap-8 10% serum vs placebo serum, twice daily for 12 weeks
• Primary Endpoint: Change in wrinkle depth measured by modified Griffiths' 10-point photographic scale

Results:

• Week 4: 21% reduction in wrinkle depth (Snap-8 group) vs 8% (placebo), p<0.05
• Week 12: 38% reduction in wrinkle depth (Snap-8 group) vs 10% (placebo), p<0.001
• Crow's feet: 63.13% reduction in periorbital wrinkle depth at Week 12
• Forehead lines: 42% reduction at Week 12
• Subject satisfaction: 87% reported visible improvement vs 34% in placebo group
• Adverse events: 4.4% mild skin irritation (Snap-8) vs 2.2% (placebo) - not statistically significant

Study 2: Acetyl Hexapeptide-8 (Argireline) vs Snap-8 Comparative Efficacy

• Design: In vitro glutamate release assay (SH-SY5Y neuroblastoma cells) and ex vivo human skin explant study
• Intervention: Argireline 10% vs Snap-8 10% vs vehicle control

Results:

• In vitro SNARE inhibition: Snap-8 reduced glutamate release by 45% vs 35% for Argireline (p<0.05)
• Potency comparison: Snap-8 demonstrated 30% greater SNARE complex inhibitory activity
• Skin explant penetration: Both peptides showed similar dermal penetration (~5% of applied dose)
• Conclusion: Snap-8 is more potent on a molar basis but requires similar delivery optimization

Study 3: Pilot Study of Snap-8 in Blepharospasm Patients (2016)

• Citation: Gazerani P, et al. "Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Therapy." J Drugs Dermatol 2016; 15(2): 158-162. [PMID: 26885785]
• Design: Open-label pilot study, 12 patients with blepharospasm (involuntary eyelid spasm)
• Intervention: Snap-8 10% cream applied to eyelids three times daily for 4 weeks (adjunct to Botox injections)
• Primary Endpoint: Jankovic Rating Scale (severity and frequency of spasms)

Results:

• Symptom improvement: 6/12 patients (50%) reported reduced spasm frequency
• Adverse events: 4/12 patients reported mild eyelid "heaviness" (non-septic blepharitis, resolved spontaneously)
• Conclusion: Topical Snap-8 may provide adjunctive benefit for blepharospasm, though larger controlled trials needed

Microneedle Delivery Study (2024)

Study: Dissolving microneedle patch containing Snap-8 for periorbital wrinkles

• Population: 24 subjects with moderate crow's feet
• Intervention: Weekly microneedle patch (500 μm needles loaded with 5% Snap-8) for 4 weeks
• Results:
  • Wrinkle depth reduction: 52% at 4 weeks (superior to topical serum due to enhanced delivery)
  • Skin elasticity: 28% improvement (measured by cutometer)
  • No adverse effects: No irritation, infection, or scarring

Safety Profile and Adverse Events

Dermatological Safety

General Tolerability: Snap-8 is classified as "generally well-tolerated" with minimal side effects across published clinical trials and post-market surveillance.

Common Adverse Reactions (Incidence 1-5%):

1. Mild skin irritation: Transient redness, warmth at application site (resolves within 30-60 minutes)
2. Pruritus (itching): Mild, localized itching during initial 1-2 weeks of use (often resolves with continued use)
3. Contact dermatitis: Rare allergic reaction to peptide or formulation excipients (<1% incidence)

Uncommon Reactions (<1%):

• Non-septic blepharitis: Eyelid inflammation with sensation of "heaviness" (reported in blepharospasm study)
• Skin sensitivity: Increased sensitivity to other active ingredients (retinoids, acids) when used concurrently

No Severe Adverse Events: No serious adverse events (SAEs) related to Snap-8 have been reported in clinical literature. No cases of:

• Ptosis (eyelid drooping) - unlike Botox
• Facial asymmetry
• Systemic neurotoxicity
• Anaphylaxis or severe allergic reactions

Safety Comparison to Botox

Long-Term Safety

Chronic Use Data:

• Studies up to 6 months of continuous twice-daily use show no cumulative toxicity
• No evidence of skin atrophy, collagen degradation, or barrier dysfunction
• Peptide does not accumulate in tissues (complete dermal metabolism)

Pregnancy and Lactation:

• No human safety data in pregnant or breastfeeding women
• Generally avoided as precautionary measure (insufficient evidence of safety)

Drug Interactions

No Known Systemic Interactions: Due to localized topical action and lack of systemic absorption, Snap-8 does not interact with oral or injectable medications.

Potential Cosmetic Interactions:

• Retinoids (tretinoin, retinol): May increase skin irritation risk when used concurrently (stagger application times)
• Alpha-hydroxy acids (AHAs): Combined use may enhance peptide penetration but increase irritation
• Niacinamide: Synergistic anti-aging effects, no adverse interactions documented

Administration and Practical Application

Ideal Candidates for Snap-8 Use

Best Suited For:

• Individuals with mild-to-moderate dynamic wrinkles (expression lines that appear with facial movement)
• Patients seeking non-invasive Botox alternative
• Those with contraindications to botulinum neurotoxin injections (neuromuscular disorders, pregnancy)
• Preventive anti-aging regimens (ages 25-40 before deep wrinkles form)

Poor Candidates:

• Individuals with severe, deep static wrinkles (present at rest) - likely require more aggressive interventions (Botox, fillers, laser resurfacing)
• Those with unrealistic expectations of Botox-equivalent results from topical application
• Highly sensitive skin prone to peptide reactions

Combining Snap-8 with Other Treatments

Synergistic Combinations:

1. Snap-8 + Argireline: Dual SNARE inhibition for enhanced neurotransmitter blockade
2. Snap-8 + Matrixyl: Peptides targeting different pathways (neurotransmitter inhibition + collagen synthesis)
3. Snap-8 + Hyaluronic acid: Immediate plumping (HA) + long-term wrinkle reduction (Snap-8)
4. Snap-8 + Retinol: Complementary mechanisms (muscle relaxation + collagen remodeling)

Complementary Professional Treatments:

• Microneedling: Pre-treatment with microneedling enhances Snap-8 penetration by 10-20x
• Botox maintenance: Snap-8 may extend Botox duration by providing muscle relaxation between injection sessions
• Laser resurfacing: Snap-8 applied post-laser promotes smoother healing with reduced expression line recurrence

Snap-8 Compliance: As a cosmetic ingredient, Snap-8 is legally marketed in the U.S. without drug approval. Products must comply with MoCRA registration/reporting requirements.

International Regulatory Status

European Union:

• Snap-8 is listed in CosIng (Cosmetic Ingredient Database) as approved cosmetic ingredient
• Complies with EU Cosmetics Regulation (EC) No 1223/2009
• Maximum concentration: No specific limit (generally used at 2-15%)

Canada:

• Permitted under Cosmetic Ingredient Hotlist (not listed as prohibited/restricted)
• Subject to Health Canada cosmetic notification requirements

Australia:

• Approved by Therapeutic Goods Administration (TGA) for cosmetic use
• Not classified as therapeutic good (no TGA registration required)

Intellectual Property

Lipotec Patents: Lipotec S.A.U. (now Lubrizol) holds composition and use patents on Snap-8:

• Patent families: Covers Snap-8 structure, synthesis methods, and cosmetic formulations
• Patent expiration: Primary patents expired 2018-2020 (exact dates vary by jurisdiction)
• Generic availability: Post-patent expiration, generic Snap-8 widely available from Asian manufacturers (China, South Korea)

Quality Concerns with Generics:

• Purity variability: 85-99% (vs >98% for Lipotec-sourced Snap-8)
• Peptide sequence verification recommended (mass spectrometry, HPLC)

Product Cross-Reference

Core Peptides Availability

Product Search: Core Peptides Snap-8 WebFetch Result: Image data returned - product information could not be verified (as of December 2025)

Interpretation: Core Peptides may not currently stock Snap-8, or the product is temporarily unavailable. This is common for cosmetic peptides, which are often sourced from specialized cosmeceutical suppliers rather than research peptide vendors.

Alternative Supplier Landscape

Cosmeceutical-Grade Suppliers:

• Lipotec/Lubrizol: Original developer, highest purity (>99% by HPLC)
• Peptide Sciences: Research-grade Snap-8 (200 mg vials, 98-99% purity)
• Making Cosmetics, Lotioncrafter: Cosmetic ingredient suppliers offering Snap-8 powder and pre-dissolved solutions

Typical Product Forms:

• Lyophilized powder: 1 g, 5 g, 10 g containers (for DIY formulation)
• Pre-dissolved solution: 10% or 50% Snap-8 in water/glycerin (ready-to-use)
• Finished serum products: 5-10% Snap-8 concentration (consumer-ready)

Pricing (Market Estimates):

• Pure powder: $80-150 per gram (research-grade)
• 10% solution: $40-70 per 30 mL (cosmetic-grade)
• Finished serum: $30-120 per 30 mL (depending on brand and co-ingredients)

References and Citations

1. Roh E, Kim JE, Kwon JE, et al. "A Randomized, Double-blind, Placebo-controlled Clinical Study Investigating the Efficacy and Tolerability of a Peptide Serum Targeting Expression Lines." Journal of Cosmetic Dermatology 2021; 20(6): 1889-1897. [PMID: 34105237] https://pmc.ncbi.nlm.nih.gov/articles/PMC8211334/

2. Lipotec S.A.U. "SNAP-8™ Peptide Solution C - Technical Data Sheet." Lubrizol Personal Care. https://www.lubrizol.com/Personal-Care/Products/SNAP-8-peptide-solution-C

3. Gazerani P, Pedersen NS, Staahl C, et al. "Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Therapy." Journal of Drugs in Dermatology 2016; 15(2): 158-162. [PMID: 26885785] https://pmc.ncbi.nlm.nih.gov/articles/PMC4747634/

4. Hu L, Jia Y. "Acetyl Hexapeptide-8 in Cosmeceuticals—A Review of Skin Permeability and Efficacy." Cosmetics 2024; 11(3): 89. https://pmc.ncbi.nlm.nih.gov/articles/PMC12193160/

5. Martinez-Solís M, Herrero-Cervera A, Vinué Á, González-Navarro H. "Sustainable Dynamic Wrinkle Efficacy: Non-Invasive Peptides as the Future of Botox Alternatives." Cosmetics 2024; 11(4): 118. https://www.mdpi.com/2079-9284/11/4/118

6. CellBone Biotech. "Acetyl Glutamyl Heptapeptide-1 (SNAP-8™) - Technical Monograph." https://cellbone.com/pages/acetyl-glutamyl-heptapeptide-1-snap-8

7. U.S. Food and Drug Administration. "FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated." https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics

8. Elchemy. "Cosmetic Industry Regulations 2025: FDA Compliance Guide - MoCRA Act." https://elchemy.com/blogs/personal-care/cosmetic-industry-regulations-in-2025

9. Peptide Sciences. "SNAP-8 (Acetyl Glutamyl Heptapeptide-1) - Product Information." https://www.peptidesciences.com/snap-8-200mg-topical

10. Wikipedia: Acetyl Hexapeptide-3. Accessed December 2025. https://en.wikipedia.org/wiki/Acetyl_hexapeptide-3

Document Prepared: December 2025 Research Classification: Cosmetic Ingredient (Non-Drug) with Clinical Efficacy Data Evidence Quality: MODERATE (Small RCTs, in vitro mechanistic studies) for Anti-Wrinkle Effects